StockIQpro
NASDAQ:FATE

Fate Therapeutics Inc.

Track all markets on TradingView
Track all markets on TradingView

Fate Therapeutics Inc.'s revenue fell 51.2% in fiscal 2025 to $6.6M while operating margin fell to −2222.4%, its lowest in 10 years. Free cash flow was −$112.0M, −1685.8% of revenue, and the diluted share count rose 4.5%.Summary generated from Fate Therapeutics Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$6.6M
Revenue growth−51.2%
Revenue, 5-yr CAGR−26.7%
Gross marginn/a
Operating margin−2222.4%
Net margin−2051.1%
ROICn/a
Return on equity−51.8%
Debt / equityn/a
Free cash flow−$112.0M
FCF margin−1685.8%
Share count change+4.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue569664147
Operating income−217−308−191−210−148
Net income−212−282−161−186−136
Free cash flow−214−284−138−124−112

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)